CORE--PSYCHOPHARMACOLOGY/BIOMEDICAL RESEARCH

精神药理学/生物医学研究实验室一直是 自1986年成立以来，儿童权利委员会一直是儿童权利委员会的重要组成部分。重大发现 有包括用标准治疗抑郁症的论证 三环类药物即使对最古老和最虚弱的 患者，这些抑郁与“不能茁壮成长”和 痴呆症的治疗反应与其他疾病不同， 治疗晚年医学疾病的常用药物 会导致精神症状。它提供持续的基础设施，以 通过开展其药理学和生物医学研究 自己的内在研究，促进与CRC的合作研究 科学家和其他人，以及广泛开展的外联/咨询活动 一系列调查人员和受训人员。它还积极参与 治疗精神障碍的多中心临床试验 晚年生活，并致力于发展这些研究。此应用程序请求 支持实验室继续提供有利的 这条调查路线的基础设施。它还请求支持 对于三个具体的试点调查：1)双盲、安慰剂- 文拉法新治疗慢性阻塞性肺疾病的随机对照临床试验 与骨关节炎相关的抑郁和疼痛。这是一个 干预发展研究旨在提供有关 药物治疗对最常见致残性疾病的价值 在晚年生活中，提高我们对治疗相关的认识 抑郁和疼痛之间的相互作用。2)关于艾滋病患病率的研究 皮质下和深层白质高信号，以及它们的 与认知(例如，执行功能)缺陷和 快感缺乏或冷漠(非抑郁)的糖尿病患者。这项研究是 旨在确定高危患者是否有亚临床症状 脑血管疾病“表现出的精神症状可能是 (主要或次要的)预防性干预。3)探索性研究 炎性细胞因子的行为药理学。这些遗嘱 包括对健康的年轻成年志愿者的挑战研究 伤寒疫苗的主观、行为和生理反应， 虚弱老年肿瘤坏死患者的临床及治疗研究 对抗者。这项研究旨在开发治疗模型。 细胞因子介导的疾病行为和抑郁。

The Laboratory for Psychopharmacological/Biomedical Research has been a key component of the CRC since its inception in 1986. Significant findings have include the demonstration that treatment of depression with standard tricyclic agents remains efficacious even in the oldest and most frail of patients, that those depressions associated with "failure to thrive" and dementia differ in treatment response from other disorders and that medications commonly used for treatment of medical disorders in late life can cause psychiatric symptoms. It provides an ongoing infrastructure to enable pharmacological and biomedical research through the conduct of its own intrinsic research, facilitating collaborative research with CRC scientists and others, and outreach/consultative activities with a wide array of investigators and trainees. It also actively participates in multi-center clinical trials of the treatment of the mental disorders of late life, and works to develop these studies. This application requests support for the Laboratory to continue to provide an enabling infrastructure for this line of investigation. It also requests support for three specific pilot investigations: 1) A double-blind, placebo- controlled, randomized clinical trial of venlafaxine for the treatment of depression and pain associated with osteoarthritis. This is an intervention development study designed to provide information on the value of pharmacological treatment for the most common disabling condition in late life and to advance our understanding of the treatment-relevant interactions between depression and pain. 2) A study of the prevalence of subcortical and deep white matter hyperintensities, and of their association with cognitive (e.g., executive function) deficits and anhedonia or apathy (non-depressed) patients with diabetes. This study is designed to determine whether patients at high risk for "subclinical cerebrovascular disease" exhibit psychiatric symptoms that may targets for (primary or secondary) preventative interventions. 3) Exploratory studies of the behavioral pharmacology of the inflammatory cytokines. These will include challenge studies in healthy young adult volunteers of the subjective, behavioral and physiological responses to typhoid vaccine, and treatment studies in frail elderly patients of Tumor Necrosis Facto antagonists. The research is designed to develop models for the treatment of cytokine-mediated sickness behavior and depression.